Literature DB >> 11096689

Hemiballismus.

.   

Abstract

Hemiballismus is a rare movement disorder that can be life threatening in the absence of a rational treatment approach. The pathologic abnormality lies in the subthalamic nucleus and its afferent or efferent connections. Before the advent of effective pharmacologic treatments, patients with hemiballismus had a dismal prognosis, with physical exhaustion, injuries, and medical complications often leading to death. Advances in pharmacologic management and emphasis on supportive measures have improved the outlook for these patients, with most now surviving. Hemiballismus tends to diminish or resolve spontaneously over several months. Treatment approaches should be vigorous during the acute phase but often may be discontinued after 6 months to 1 year. Surgical treatment of hemiballismus appears promising and should be reserved for the patient with persistent movements whose disease is refractory to medical management.

Entities:  

Year:  1999        PMID: 11096689     DOI: 10.1007/s11940-999-0026-4

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  22 in total

1.  Clozapine for the control of hemiballismus.

Authors:  K Bashir; B V Manyam
Journal:  Clin Neuropharmacol       Date:  1994-10       Impact factor: 1.592

Review 2.  The pharmacology of choreatic movement disorders.

Authors:  H L Klawans; W J Weiner
Journal:  Prog Neurobiol       Date:  1976       Impact factor: 11.685

3.  Hemiballismus and secondary mania following a right thalamic infarction.

Authors:  J Kulisevsky; M L Berthier; J Pujol
Journal:  Neurology       Date:  1993-07       Impact factor: 9.910

4.  Successful treatment of hemiballismus with progabide, a new GABA-mimetic agent.

Authors:  M Gonce; J Schoenen; M Charlier; P J Delwaide
Journal:  J Neurol       Date:  1983       Impact factor: 4.849

5.  Pallidotomy for hemiballismus: efficacy and characteristics of neuronal activity.

Authors:  J I Suarez; L V Metman; S G Reich; P M Dougherty; M Hallett; F A Lenz
Journal:  Ann Neurol       Date:  1997-11       Impact factor: 10.422

Review 6.  Outcome after stereotactic thalamotomy for dystonia and hemiballismus.

Authors:  F Cardoso; J Jankovic; R G Grossman; W J Hamilton
Journal:  Neurosurgery       Date:  1995-03       Impact factor: 4.654

7.  Hemiballism-hemichorea. Clinical and pharmacologic findings in 21 patients.

Authors:  R B Dewey; J Jankovic
Journal:  Arch Neurol       Date:  1989-08

Review 8.  Movement disorders following lesions of the thalamus or subthalamic region.

Authors:  M S Lee; C D Marsden
Journal:  Mov Disord       Date:  1994-09       Impact factor: 10.338

9.  Effect of tetrabenazine on extrapyramidal movement disorders.

Authors:  M A Dalby
Journal:  Br Med J       Date:  1969-05-17

10.  Hemiballismus: CT and MR findings.

Authors:  J M Provenzale; J P Glass
Journal:  J Comput Assist Tomogr       Date:  1995 Jul-Aug       Impact factor: 1.826

View more
  1 in total

1.  Striatal neuronal loss correlates with clinical motor impairment in Huntington's disease.

Authors:  Zhihong Guo; Gay Rudow; Olga Pletnikova; Kari-Elise Codispoti; Brent A Orr; Barbara J Crain; Wenzhen Duan; Russell L Margolis; Adam Rosenblatt; Christopher A Ross; Juan C Troncoso
Journal:  Mov Disord       Date:  2012-09-13       Impact factor: 10.338

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.